Observed Signal · Nov 12, 2026 · Funding · Source: EU-Startups (European Venture) · Impact: 1/5 · Sentiment: Positive
Orakl Oncology Raises €30M for AI Cancer Drug Prediction
Orakl Oncology, a French TechBio company, announced a €30 million ($34 million) Series A round co-led by Norrsken VC and Singular, with participation from InfraVia Capital Partners, Serena, Patient Autonome Fund managed by Bpifrance, Teampact Ventures, Plug and Play, and existing investors Verve Ventures VC, Speedinvest, and HCVC. The company uses AI and patient-derived tumor organoids to build 'virtual cancer patients' that predict drug performance in clinical trials, aiming to reduce the high failure rate in Phase 2 oncology trials. Orakl claims 90% accuracy in predicting clinical outcomes. The funding will expand its platform across more cancer types and geographies. Total funding now stands at €45 million.
AI-driven drug development funding is relevant to AI in healthcare, but not directly related to AdTech, MarTech, or advertising.
Track Singular Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Orakl Oncology raised €30 million ($34 million) in a Series A round.
- The round was co-led by Norrsken VC and Singular.
- Total funding for the company is now €45 million ($50 million).
- Orakl's predictive engine claims 90% accuracy in predicting clinical trial outcomes.
- Founded in 2023, Orakl spun out of the Gustave Roussy Institute.
Connected Companies & Entities
“The round was co-led by Norrsken VC and Singular.”
“It included new investors InfraVia Capital Partners, Serena, the Patient Autonome Fund managed by Bpifrance, Teampact Ventures and Plug and ...”
“Existing investors Verve Ventures VC, Speedinvest and HCVC.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
Proximal Ventures Raises $27.5M for AI Drug Development Fund
Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Receive all future signals for Singular & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.